GlassScriptPhysician profile
Anas Younes
NPI 1124113410
$58,455.63
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $12K.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $9,375.23 | 2019 | |
| Novartis Pharmaceuticals Corporation | $8,270.50 | 2019 | |
| Daiichi Sankyo INC. | $8,249.39 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $6,635.96 | 2019 | |
| F. Hoffmann-La Roche Ag | $6,279.80 | 2019-2023 | |
| Genentech, INC. | $6,003.23 | 2019 | |
| Hoffmann-La Roche Limited | $4,619.34 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $3,625.00 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $3,100.00 | 2019 | |
| Janssen Global Services, LLC | $2,261.29 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $21.66 | 2019 | |
| Roche Products Limited | $14.23 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Research and ownership
$5,707.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anas Younes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.